---
document_datetime: 2025-05-05 11:24:33
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/clopidogrel-acetylsalicylic-acid-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: clopidogrel-acetylsalicylic-acid-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.554898
conversion_datetime: 2025-12-25 11:24:25.099424
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Clopidogrel/Acetylsalicylic acid Viatris

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproductlifecycleprocedures,please alsorefertoEPAR-Proceduralstepstakenandscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| VariationtypeIA/    | This was an application for a group of | 02/05/2025                          |                                          | Annex II and                    |           |

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000268788                    | variations. A.5Changeinthename and/oraddressof a manufacturer/importer of the finished product (including batch release or quality control testing sites)-A.5.bThe activities for which the manufacturer/importer is responsible do not include batch release - Accepted B.III.1.aEuropeanPharmacopoeial CertificateofSuitability totherelevantPh. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer-Accepted A.ADMINISTRATIVECHANGES-A.7 Deletionofmanufacturingsitesfor an active substance,intermediate orfinishedproduct, packaging site, manufacturer responsible for batchrelease,sitewherebatchcontroltakes place, or supplier of a starting material, reagent or excipient (when mentioned in the   |            | PL          |
|--------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| Variation typeIB / EMA/VR/0000246078 | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.z Change(s)in the SmPC, labelling or package leaflet of human medicinal products in order to adapt to a recommendation of a competent authority , e.g. a Core SmPC, following the assessment of anUrgentSafetyRestrictionetc.                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 27/02/2025 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

| Implementation of wording agreed by the competent authority. - Accepted C.I.z (IB) - To update sections 4.3 and 4.6 of the SmPC and section 2 of the Package Leaflet to introduce information on\"NSAID- containing medicinal products (for systemic use) and use during pregnancy\", following the CMDh recommendation (EMA/CMDh/492082/2024). Furthermore, theMarketingAuthorisationHolderhas taken theopportunity toimplementupdates   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|